Bristol Myers Squibb (BMY) announced that the FDA has granted accelerated approval to chimeric antigen receptor (CAR) T cell therapy, Breyanzi (lisocabtagene maraleucel), for one more indication.The approval was granted for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. The acce ...

Bristol Myers Squibb宣布FDA批准Breyanzi用于治疗CLL/SLL - Bristol Myers Squibb宣布FDA已加速批准Breyanzi用于治疗成人复发性或难治性慢性淋巴细胞白血病（CLL）或小淋巴细胞淋巴瘤（SLL）[1] - Breyanzi是第一个获得批准用于复发性或难治性CLL或SLL的CAR T细胞疗法，为患者提供个性化选择[2] - TRANSCEND CLL 004研究显示，Breyanzi治疗的CR率为20%，响应持续时间较长[3] FDA批准liso-cel用于CLL和SLL治疗 - FDA批准liso-cel在复发性或难治性CLL和SLL中的使用是一项重大突破，有望为患者提供完全和持久的缓解[4] BREYANZI治疗CLL/SLL患者的神经毒性反应 - BREYANZI治疗CLL/SLL患者时，46%出现CAR T细胞相关的神经毒性反应[31] - 神经毒性反应中最常见的包括脑病、震颤、失语症、头痛、眩晕和谵妄[32] - 对于CRS和神经毒性反应，需要在BREYANZI输注后至少监测7天[33] - 在BREYANZI输注后至少监测4周，及时治疗CRS和神经毒性反应[34]

SIphotography/iStock via Getty Images Get Paid To Wait The Efficient Market Hypothesis tells us that share prices reflect all available information and therefore it is effectively impossible to consistently generate alpha. Academics have long accepted this theory and provided sufficient data to prove that it's true. While there certainly are proponents of the theory, it also has its critics. Many famous investors disagree with the hypothesis and have track records that prove it cannot be true. Regardles ...

产品展示 - 公司对Abecma的临床益处感到非常自信，已在日本获得批准，并在欧洲和瑞士取得成功[5] - Abecma在早期治疗中展现出了临床益处，通过KarMMa-3试验的结果得以证实[6] - 公司对Abecma在长期商业竞争力持乐观态度，特别强调了其在早期治疗中的优势[10] - 公司相信Abecma的安全性特点将在早期治疗中发挥重要作用，与竞争对手相比具有优势[12] 新产品和技术研发 - 公司对LAG-3项目的结果感到兴奋，计划在年底前启动第三阶段研究[14] - 通过LAG-3项目，公司确定了20%至30%的患者群体将从LAG-3加PD-1加化疗中获益[14] - 公司在肺癌领域持续扩大产品组合，致力于满足不同患者的治疗需求[19] 市场扩张和并购 - RayzeBio的收购为BMS带来了资产、IND引擎和制造能力，将有助于细胞疗法平台的发展[57] - BMS对于SystImmune的合作机会感到兴奋，这将有助于公司在肺癌和乳腺癌领域进一步发展[58]

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this biopharmaceutical company have returned +7.7% over the past month versus the Zacks S&P 500 composite's +4.4% change. The Zacks Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, has gained 4% over this period. Now the key question is: Where could the s ...

新产品和新技术研发 - Bristol-Myers Squibb即将在今年晚些时候获得KarXT的批准[6][7] - 公司正在进行多个适应症的研究，如银屑病性关节炎和cendakimab[9] - 推进milvexian在房颤二级预防、急性冠状动脉综合征等三个适应症的研究[10] - 拥有最大的细胞治疗目标，包括已获批准的Breyanzi和Abecma，以及即将进入关键阶段研究的GPRC5D等[11] 未来展望 - 公司正考虑重新调整产品组合，优化投资组合，退出某些产品，以确保未来的转型成果[16][17][18] - Bristol-Myers Squibb将重点关注Opdualag、Krazati、KarXT等重要产品的发展，以及在SLE治疗方面的持续招募[30][33][34] 市场扩张和并购 - 公司正在考虑重新调整产品组合，以确保未来的转型成果[16][17][18] 其他新策略和有价值的信息 - MYK-224是一种心肌肌凝蛋白抑制剂，将在今年上半年产生第二阶段MERCUTIO数据[53] - MYK-224是下一代产品，首先在梗阻性肥厚型心肌病中进行测试，以便与CAMZYOS数据进行比较[54] - MYK-224还在进行心力衰竭伴随保留射血分数的2a期研究[55]

公司研发项目 - 公司首席医疗官Samit Hirawat介绍了公司的研发愿景和当前的研发项目[2] - 公司在神经学领域取得了重大进展，即将推出KarXT产品，涉及精神分裂症等多个适应症[3] - 公司在免疫学、心血管疾病、血液学、肿瘤学和细胞疗法等领域有多个重要项目在进行[4] 产品组合优化 - 公司正在考虑优化产品组合，可能会退出某些产品，以实现更大的转型性成果[15] - 公司正在进行深入审视现有产品组合，以确保未来的研发项目具有转型性价值[18] 重要研发项目发布计划 - 公司将在未来一两年内推出多个重要研发项目，包括Opdualag、Krazati等[26] - 公司将在今年内推出多个重要研发项目，包括KarXT的批准、cendakimab的数据等[32] 产品研发数据和评估 - 公司对Opdualag的数据进行了初步分析，计划在未来公布更多数据[28] - 公司对Opdualag的潜在患者群体进行了重要性评估，但未透露具体细节[33] 临床试验和研究设计 - 公司确认在Phase 3试验中，KEYTRUDA加化疗将作为对照组[36] - 公司设计了Opdivo plus relatlimab与nivo plus chemo的研究，以评估安全性和有效性[39] 未来研发项目展望 - 公司的tau项目进入第2期研究阶段，与竞争对手Biogen的Tau ASO项目有所区别，重点关注安全性、认知和功能评估[72][73][74][75][76][77][78]

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2024 on Thursday, April 25, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Investors and the public can register for the live conference call here. Those una ...

5 Top Dividend Stocks Passive Income Investors Should Buy in March jittawit21 / Shutterstock.com Investors love dividend stocks because they provide dependable income and give investors a great opportunity for solid total return. Total return includes interest, capital gains, dividends, and distributions realized over time. In other words, the total return on an investment or a portfolio consists of income and stock appreciation. At 24/7 Wall St., we always remind our readers about the impact total return ...

JHVEPhoto After a period in purgatory, Bristol-Myers Squibb Company (NYSE:BMY) finally returned back into growth mode, though relatively slow. The biopharma has faced a period of excruciating LOEs on key drugs like Revlimid pressuring sales. My investment thesis remains Bullish on the biopharma stock, even after a solid bounce off the lows. Source: Finviz Turnaround Quarter Bristol-Myers just reported a quarter where sales actually returned to growth after a period of 5 quarters with sales dipping YoY. For ...